Atropa belladonna (Belladonna)

Belladonna (Atropa belladonna) contains tropane alkaloids—primarily atropine and scopolamine—that act as competitive antagonists at muscarinic acetylcholine receptors, producing anticholinergic effects across smooth muscle, cardiac, and glandular tissues. These compounds have been studied for applications ranging from gastrointestinal spasm relief to cardiac support and pain management.

Origin & History

Atropa belladonna (deadly nightshade) is a perennial herbaceous plant native to Europe, North Africa, and western Asia, belonging to the Solanaceae family. The plant's leaves, roots, and berries serve as the primary source of tropane alkaloids, extracted via solvent extraction or enhanced through genetic modification methods like CRISPR/Cas9 targeting hyoscyamine 6β-hydroxylase.

Historical & Cultural Context

Belladonna has been used in European folk medicine and traditional systems for centuries to treat gastrointestinal spasms, asthma, bronchitis, jaundice, and motion sickness. Traditional formulations include belladonna-phenobarbital for spasmodic disorders, though historical use has been limited by its toxicity profile.

Health Benefits

• May help manage acute encephalitis syndrome symptoms (systematic review of 20 studies, n=2302)
• Shows potential for reducing urethral stent pain (systematic review evidence)
• May support cardiac function in myocardial ischemia injury (systematic review evidence)
• Could help with irritable bowel syndrome symptoms (systematic review evidence)
• May provide relief from throbbing headaches (systematic review evidence)

How It Works

The primary bioactive alkaloids in Atropa belladonna—atropine (dl-hyoscyamine) and scopolamine (hyoscine)—competitively antagonize muscarinic acetylcholine receptors (M1–M5 subtypes), blocking parasympathetic nerve transmission at smooth muscle, cardiac sinoatrial nodes, and exocrine glands. Atropine's blockade of cardiac M2 receptors increases heart rate and improves atrioventricular conduction, which underlies its proposed benefit in myocardial ischemia models. Scopolamine's preferential binding to M1 and M3 receptors contributes to antispasmodic and antisecretory effects in gastrointestinal tissue, reducing smooth muscle contractility via inhibition of phospholipase C–mediated intracellular calcium release.

Scientific Research

A systematic review (1965-2020) analyzing 20 studies with 2,302 patients found belladonna safe and effective for multiple conditions using GRADE methodology (PMID: 32662978). One single-blind placebo-controlled RCT (n=8) tested Atropa belladonna tincture showing dose-dependent vagolytic and vagotonic effects (PMID: 11485281). However, no large-scale RCTs or meta-analyses with standardized extracts were identified, limiting evidence to smaller trials.

Clinical Summary

A systematic review encompassing 20 studies (n=2,302) examined belladonna alkaloids in the context of acute encephalitis syndrome symptom management, though evidence quality varied and conclusions require cautious interpretation. Systematic review evidence also supports the use of belladonna-derived alkaloids for reducing urethral stent-related pain, with anticholinergic mechanisms dampening smooth muscle spasms in the urinary tract. Cardiac applications in myocardial ischemia injury have been explored in systematic review-level evidence, suggesting atropine's M2 antagonism may confer cardioprotective benefit, though most underlying studies are preclinical or small-scale. Evidence for irritable bowel syndrome relief is mechanistically plausible given antispasmodic activity, but robust, large-scale randomized controlled trial data specifically for whole-plant belladonna extracts remains limited.

Nutritional Profile

Atropa belladonna is a medicinal plant, not a food source, and is not consumed for nutritional value due to its high toxicity. Nutritional macronutrient data (carbohydrates, proteins, fats) is not documented for dietary purposes. Key bioactive compounds include: Tropane alkaloids (primary constituents) — atropine (dl-hyoscyamine) at approximately 0.3–0.6% in leaves and 0.4–0.8% in roots (dry weight); l-hyoscyamine (the biologically active enantiomer, comprising the majority of total alkaloid content before racemization); scopolamine (hyoscine) at approximately 0.06–0.3% in leaves; apoatropine and belladonnine as minor alkaloids. Total alkaloid content in leaves ranges from 0.3–1.0% dry weight, with roots containing 0.4–1.3%. Phenolic compounds include chlorogenic acid, caffeic acid, and flavonoids (quercetin, kaempferol glycosides) at trace concentrations (estimated 0.1–0.5% dry weight). Coumarins including scopoletin have been identified. The berries contain solanine-related glycoalkaloids. Carotenoids (including lutein and beta-carotene) are present in minor quantities in the leaves. Bioavailability note: Atropine and hyoscyamine are rapidly absorbed through mucous membranes, skin (transdermal), and the gastrointestinal tract with high systemic bioavailability (~90%); scopolamine crosses the blood-brain barrier readily. All parts of the plant are poisonous — the lethal dose of atropine in adults is estimated at 10 mg, and 2–5 berries may be fatal to children. No conventional vitamins or dietary minerals have been characterized in meaningful concentrations.

Preparation & Dosage

Clinically studied oral doses include Atropa belladonna tincture (0.1 mg/ml alkaloids) at 1 ml (vagotonic effects), 2 ml (low-moderate), and 5 ml (vagolytic effects), with atropine/scopolamine ratio 20:1. No standardized extract dosages or powder forms were specified in trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Phenobarbital (traditional combination), physostigmine (as antidote only), activated charcoal (poisoning management), midazolam (toxicity treatment)

Safety & Interactions

Belladonna alkaloids carry a narrow therapeutic index; even modest overdoses can cause anticholinergic toxidrome characterized by tachycardia, mydriasis, dry mucous membranes, urinary retention, hyperthermia, and central nervous system agitation or delirium. Belladonna is contraindicated in individuals with angle-closure glaucoma, benign prostatic hyperplasia, myasthenia gravis, and tachyarrhythmias. Significant drug interactions occur with other anticholinergic agents (additive toxicity), antihistamines, tricyclic antidepressants, and monoamine oxidase inhibitors; it may also reduce the absorption of certain oral medications by slowing gastric motility. Belladonna is classified as unsafe during pregnancy due to teratogenic potential of tropane alkaloids and is not recommended during breastfeeding, as atropine is excreted in breast milk and can cause infant toxicity.